Evidence map›Paper›PMID 41627500›Full record

ArticleCellular and molecular life sciences : CMLS2026

Interaction between HIV-1 Tat and EBV Zta favours immune escape of B cells by downregulating HLA-ABC expression.

Anna Shmakova, Anna Schwager, Ivan Tsimailo, Emile Clerf, Yana Kozhevnikova, Junyi Feng, Laurence Gérard, David Boutboul, Eric Oksenhendler, Mohammed Habib and 3 more

Abstract read
In one paragraph

Article in Cellular and molecular life sciences : CMLS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anna ShmakovaCNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800, France.ORCID http://orcid.org/0000-0001-7162-074X
Anna SchwagerKoltzov Institute of Developmental Biology, Moscow, 119334, Russia.
Ivan TsimailoCNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800, France.
Emile ClerfCNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800, France.
Yana KozhevnikovaCNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800, France.
Junyi FengCNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800, France.
Laurence GérardService d'Immunopathologie Clinique, Hôpital St Louis, APHP, Paris, 75012, France.
David BoutboulService d'Immunopathologie Clinique, Hôpital St Louis, APHP, Paris, 75012, France.
Eric OksenhendlerService d'Immunopathologie Clinique, Hôpital St Louis, APHP, Paris, 75012, France.
Mohammed HabibCIBB-IBS UMR 5075 Université Grenoble Alpes, Grenoble, 38044, France.
Emmanuel DrouetCIBB-IBS UMR 5075 Université Grenoble Alpes, Grenoble, 38044, France.
Diego GerminiCNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800, France.
Yegor VassetzkyCNRS, UMR 9018, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, 94800, France. yegor.vassetzky@cnrs.fr.ORCID http://orcid.org/0000-0003-3101-7043

Funding

Agence Nationale de Recherches sur le Sida et les Hépatites Virales SARSTUBVARIDB RAS Government basic research program 0088-2024-0010
6 · The paper itself

Abstract

Both Human immunodeficiency virus (HIV) and Epstein-Barr Virus (EBV) are associated with an increased risk of malignancies. HIV infection is associated with EBV reactivation and an increase in EBV viral loads in saliva and blood, and people living with HIV frequently develop EBV-associated B-cell malignancies. In this study, we aimed to investigate the involvement of HIV-1 and EBV co-existence in the development of B-cell malignancies. To do so, we focused our attention on the two viral transcriptional activators (HIV-1 Tat and EBV Zta) and analyzed their possible interaction since they both have cell-penetration domains and can be found simultaneously in the blood or cells of people living with HIV. We investigated the interaction of Tat and Zta using co-immunoprecipitation, in vitro binding, YFP reconstitution assay and FRET. We found that they bind each other in human B cells and blood serum. Tat and Zta interaction was also observed in a serum sample from one HIV-positive individual. YFP reconstitution demonstrated that this interaction occurred predominantly in the nucleus, indicating that it might affect the host genome. We further analyzed the effects of Tat and Zta on primary and EBV-transformed human B cells by RNA-sequencing and found that the combined Tat and Zta action in B cells differed from a single action of the two proteins. A subset of genes, activated by Tat or Zta alone, that trigger an immune response and antigen presentation in B cells, remained unchanged when the two proteins were combined. B cells, treated or transfected with Tat and Zta, exhibited a substantial decrease in HLA-ABC (MHC class I) expression, a critical component of the antigen processing and presentation pathway. Our findings suggest that the reduction of total HLA-ABC levels in B cells upon Tat and Zta interaction might be linked to HLA-ABC proteasomal degradation. Furthermore, HLA-ABC downregulation induced by Tat and Zta interaction conferred protection against cytotoxic T cell recognition of EBV-infected B cells. To conclude, we demonstrated for the first time that HIV-1 Tat and EBV Zta interacted directly in B cells and blood serum; this interaction can be found in people with HIV. This interaction brings about immune evasion of EBV-infected or transformed B cells.

Indexed as

B-LymphocytesHerpesvirus 4, HumanHIV-1Immune Evasiontat Gene Products, Human Immunodeficiency VirusTrans-ActivatorsDown-RegulationEpstein-Barr Virus InfectionsHIV InfectionsHumansProtein BindingBZLF1 protein, Herpesvirus 4, Humantat Gene Products, Human Immunodeficiency VirusTrans-ActivatorsB cellsEBVEBV Zta (BZLF1)HIVHIV-1 TatImmune evasionInterviral protein-protein interaction

Identifiers

PMID41627500
PMCPMC12876532

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.